- JP-listed companies
- Delta-Fly Pharma, Inc.
- Income statement
Delta-Fly Pharma, Inc. (4598) Income statement
Market cap
¥2.1B
P/E ratio
-1.2x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 409 | 145 | 902 | 150 | - | 100 | 300 | 300 | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | ||||
| Operating margin (%) | - | - | - | - | - | - | - | ||||
| Operating income | - | - | - | -244 | -593 | -1,546 | -852 | -961 | -1,316 | -1,403 | -1,708 |
| Income before tax | -288 | -596 | 323 | -245 | -671 | -1,552 | -859 | -964 | -1,326 | -1,427 | -1,719 |
| Pretax margin (%) | -70.5 | -410.2 | 35.8 | -163 | - | -1,552.2 | -286.5 | -321.4 | - | - | - |
| Provision for income taxes | - | - | - | 2 | 3 | 4 | 3 | 3 | 3 | 3 | 3 |
| Effective tax rate (%) | - | - | - | ||||||||
| Net income | -290 | -598 | 305 | -246 | -674 | -1,556 | -863 | -967 | -1,329 | -1,429 | -1,721 |
| Net income margin (%) | - | - | - | - | |||||||
| Earnings per share | -127.65 | -185.53 | 88.31 | -71.2 | -170.16 | -348.32 | -187.34 | -178.58 | -234.51 | -198.78 | -195.58 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||||
| EBITDA margin (%) | - | - | - | - | - | - | - |